The newest solution proposed by Petersen et al. is the use of a bimodal molecule, integrating an NMDA receptor antagonist MK-801 with GLP-1 receptor agonism, effectively reversing obesity, hyperglycemia, and dyslipidemia in rodent models of metabolic disease. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.